What it sells
Software to speed up pharma commercial (sales) calls
Business model breakdown
Buyer: who owns the budget?
UnverifiedCompetitive intelligence / commercial strategy directors at large pharma companies.
Trigger: what makes them buy now?
Slow vendor-written alerts (about 4 hrs vs 14 min with Pharosyn) and time-critical congress coverage where summaries arrive late at night; top-10 pharma users cite hours-to-minutes turnaround.
Workflow: what inputs become what output?
Automated monitoring of clinical and regulatory events, deals, hiring, epidemiology and social media with tailored scopes, producing alerts and reports; replaces slow outsourced vendors.
Economics: what it saves and how it charges
Claims 94% average reduction in time-to-deliverable versus legacy vendors (4 hrs to 14 min).
Distribution: how it reaches customers
Request-based sales ('Submit a request'), team-supported service.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-09-02 | Seed | $3M | — | app.dealroom.co |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.